EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte Studie

First-line biologics as a treatment for ulcerative colitis: a multicenter randomized control study

Makoto Naganuma iD, Hisashi Shiga, Masayuki Shimoda, Minoru Matsuura, Kento Takenaka, Toshimitsu Fujii, Shojiro Yamamoto, Mao Matsubayashi, Taku Kobayashi, Nobuo Aoyama, Daisuke Saito, Kaoru Yokoyama und 22 weitere

Journal of Gastroenterology · 2025-04 · 60 (4) · 430-441

DOI: 10.1007/s00535-025-02216-0 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Gastroenterology, online erschienen am 30.01.2025. Verfasst von Makoto Naganuma und 33 weiteren Autor:innen. Beteiligte Einrichtung: Third Department of Internal Medicine, Kansai Medical University, 2-5-1 Shinmachi, Hirakata, Osaka, 573-1010, Japan. naganuma@hirakata.kmu.ac.jp. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Infliximab, Ustekinumab, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: the Japan Agency for Medical Research and Development, Ministry of Health, Labour and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Despite the availability of several biologics for ulcerative colitis (UC), there remains a critical need to identify first-line treatment biologics. The superiority of infliximab (IFX) over vedolizumab (VED) and ustekinumab (UST) was evaluated as initial UC treatments in patients with biologic-naïve UC. METHODS: This multicenter, randomized control trial was conducted across 20 Japanese medical institutions. An independent center randomly allocated patients with UC (Mayo score ≥ 6) who had not previously used biologics to three treatment groups (IFX, VED, UST). The primary endpoint was the clinical remission (CR) rate at week 12, with other endpoints including the treatment continuation rate at week 26 and adverse events (AEs). RESULTS: From May 2021 to June 2023, 107 cases were registered, including 104 for safety and 97 for efficacy evaluation. CR rate at week 12 was 36.4% (95%CI:20.4-54.9), 32.4% (95%CI:17.4-50.5) and 43.3% (95%CI:25.5-62.6) in IFX, VED, and UST group, respectively. Continuation rates at week 26 were 50.0%(IFX), 58.3% (VED), and 82.4% (UST). AEs related to study medication were 14.7% (IFX), 16.7% (VED), and 5.9% (UST). Predictors for CR at week 12 were thiopurine use in IFX (p = 0.04), lower baseline Mayo score (p = 0.007), and lower Patient report outcome 2 (p = 0.003) at week 2 in VED. CONCLUSION: Due to small sample size, it is challenging to make conclusions for main endpoints from this study while our study suggested that use of thiopurines in IFX group and lower activity at enrollment in VED group may enhance treatment efficacy. (jRCT1031200329; available at https://jrct.niph.go.jp/ ).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeInfliximabUstekinumabAntibodies, Monoclonal, HumanizedGastrointestinal AgentsBiological ProductsHumansMaleFemaleMiddle AgedAdultTreatment OutcomeJapanRemission InductionAged

Stichwörter der Autor:innen

Clinical remissionInfliximabRandomized control trialUstekinumabVedolizumab

Substanzen

InfliximabvedolizumabUstekinumabAntibodies, Monoclonal, HumanizedGastrointestinal AgentsBiological Products

Autor:innen und Institutionen

  • Third Department of Internal Medicine, Kansai Medical University, 2-5-1 Shinmachi, Hirakata, Osaka, 573-1010, Japan. naganuma@hirakata.kmu.ac.jp.
  • Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Department of Pathology, The Jikei University School of Medicine, Tokyo, Japan.
  • Department of Gastroenterology and Hepatology, Kyorin University School of Medicine, Mitaka, Japan.
  • Department of Gastroenterology and Hepatology, Institute of Science Tokyo, Tokyo, Japan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.

ORCID-Profile: Makoto Naganuma

Förderung

  • the Japan Agency for Medical Research and Development
  • Ministry of Health, Labour and Welfare

Zitieren

APA

Naganuma, M., Shiga, H., Shimoda, M., Matsuura, M., Takenaka, K., Fujii, T., Yamamoto, S., Matsubayashi, M., Kobayashi, T., Aoyama, N., Saito, D., Yokoyama, K., Moriya, K., Tsuchiya, K., Shibui, S., Kawamoto, A., Shimizu, H., Okamoto, R., Sakamoto, K., …, & Collaborators of the Study (2025). First-line biologics as a treatment for ulcerative colitis: a multicenter randomized control study. Journal of Gastroenterology, 60(4), 430-441. https://doi.org/10.1007/s00535-025-02216-0

Vancouver

Naganuma M, Shiga H, Shimoda M, Matsuura M, Takenaka K, Fujii T, et al. First-line biologics as a treatment for ulcerative colitis: a multicenter randomized control study. Journal of Gastroenterology. 2025;60(4):430-441. doi:10.1007/s00535-025-02216-0

BibTeX
@article{Naganuma2025,
  author = {Naganuma, Makoto and Shiga, Hisashi and Shimoda, Masayuki and Matsuura, Minoru and Takenaka, Kento and Fujii, Toshimitsu and Yamamoto, Shojiro and Matsubayashi, Mao and Kobayashi, Taku and Aoyama, Nobuo and Saito, Daisuke and Yokoyama, Kaoru and Moriya, Kei and Tsuchiya, Kiichiro and Shibui, Shunsuke and Kawamoto, Ami and Shimizu, Hiromichi and Okamoto, Ryuichi and Sakamoto, Kazuki and Yaguchi, Katsuki and Kunisaki, Reiko and Akiyama, Shintaro and Hayashi, Ryohei and Hasui, Keisuke and Kanmura, Shuji and Bamba, Shigeki and Mishima, Yoshiyuki and Kakimoto, Kazuki and Sugimoto, Shinya and Nakazawa, Atsushi and Abe, Takayuki and Ogata, Haruhiko and Hisamatsu, Tadakazu and Collaborators of the Study, Collaborators of the Study},
  title = {First-line biologics as a treatment for ulcerative colitis: a multicenter randomized control study},
  journal = {Journal of Gastroenterology},
  year = {2025},
  volume = {60},
  number = {4},
  pages = {430--441},
  doi = {10.1007/s00535-025-02216-0}
}
Kostenlos starten →